Skip to main content


Not yet reviewed

About me

Ms. Ehrlich represents clients regulated
by the US Food and Drug Administration, Federal Trade Commission,
Consumer Product Safety Commission, Drug Enforcement Administration,
Department of Agriculture, and other health and safety regulatory
agencies at both the Federal and State level. While her practice includes all aspects of consumer product regulation,
Ms. Ehrlich has particular expertise with the marketing and labeling
of dietary supplements, cosmetics and conventional foods, pharmaceutical and
medical device clearance and marketing, Lanham Act false advertising
and administrative litigation, and privacy issues affecting pharmaceutical
and medical device companies.  Ms. Ehrlich advises clients in a
wide range of matters, including issues related to pharmacy compounding, non-patent
exclusivity, and health care fraud and abuse.


Contact info

Kleinfeld, Kaplan and Becker, LLP

1140 19th Street Northwest
Washington, DC, 20036

Practice areas


  1. Life Sciences: 50%
    21 years
  2. Administrative Law: 50%

Attorney endorsements

No endorsements

Endorsements from fellow lawyers are an important consideration for many when selecting the right attorney. Be the first to endorse your colleague!

Are you an attorney? Endorse this lawyer


DCActive 199507/06/2016
GAResigned Membership 199407/15/2016
We have not found any instances of professional misconduct for this lawyer.
Avvo contributions
Legal answers
Work experience
TitleCompany nameDuration
PartnerKleinfeld, Kaplan and Becker, LLP1996 - Present
AssociateHogan & Hartson1994 - 1996
N/AHon. Alexander B. Denson1993 - 1994
Association namePosition nameDuration
Food and Drug Law InstituteMemberN/A
American Bar AssociationMemberN/A
District of Columbia BarMemberN/A
District of Columbia BarMemberN/A
State Bar of GeorgiaMemberN/A
Publication nameTitleDate
Regulatory Affairs FocusPrescription Drug Television Advertisement Advisory Review Fees — Not This Year2008
Regulatory Affairs FocusThe New Prescription Drug Television Advertisement Advisory Review Fees2007
FDLI UpdateValue-Added Program Review Committees — A Key Step Toward Effective Corporate Compliance2003
How to Work with the FDA After the Inspection: Addressing the 483 and the Establishment Inspection Report2002
PDMA Inc. UpdateUpdate of the Final Prescription Drug Marketing Act Regulations2001
PDMA Inc. UpdateIllegal Sampling Practices May Result in Huge Settlements2001
FDLI UpdateDrink Yourself to Good Health and Inner Peace — Marketing Beverage-Type Products Containing Herbal Ingredients as Dietary Supplements2001
How to Work with the FDA: Tips from the ExpertsAfter the Inspection: Addressing the 483 and the Establishment Inspection Report2000
FDLI UpdateFDA’s Regulation of Over-the-Counter Drug/Dietary Supplement Combination Products2000
The Regulatory Affairs JournalRelief for Tired Eyes: The US FDA’s New OTC Drug Labelling Requirements1999
School nameMajorDegreeGraduated
Harvard University Law SchoolLawJD - Juris Doctor1993
Emory UniversityN/ABA - Bachelor of Arts1990
Hebrew UniversityN/AN/A1989
Speaking engagements
Conference nameTitleDate
Introduction to Medical Device Law and Regulation WorkshopInternational Issues2007
Introduction To Drug Law And Regulation The New Drug Approval Requirement2004
The Changing Environment of BiologicsExpedited Approval and Orphan Exclusivity2001
Introduction to Drug Law and RegulationThe Abbreviated NDA and Patent Exclusivity Issues2001
Successfully Filing Variations Under the New System in EuropeIndications Variations in the United States1997